DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Samelson EJ, Miller PD, Christiansen C. , et al.
RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.
J Bone Miner Res 2014;
29 (02) 450-457
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.